Norway vs Saint Kitts and Nevis: Immunization, Hib3
Norway
97.0%
in 2024
Saint Kitts and Nevis
97.0%
in 2024
Norway rank
29th
Saint Kitts and Nevis rank
29th
Immunization, Hib3 over time
- Norway
- Saint Kitts and Nevis
How they compare
Norway currently reports 97.0% against 97.0% in Saint Kitts and Nevis, a difference of 0.0%.
The two have swapped places 5 times across 25 shared years of data; in 2000 it was Norway ahead.
Norway ranks 29th and Saint Kitts and Nevis ranks 29th of 191 countries.
Across the 3 decades both report, Norway averaged higher in 1 and Saint Kitts and Nevis in 1.
Head to head by decade
| Decade | Norway | Saint Kitts and Nevis | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 94.1% | 89.1% | 5.0% | Norway |
| 2010s | 95.3% | 97.2% | 1.9% | Saint Kitts and Nevis |
| 2020s | 96.8% | 96.8% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Norway or Saint Kitts and Nevis?
- Norway, at 97.0% against 97.0% in Saint Kitts and Nevis as of 2024.
- What is the difference in immunization, hib3 between Norway and Saint Kitts and Nevis?
- 0.0%, with Norway ahead.
- How many years of comparable data are there for Norway and Saint Kitts and Nevis?
- 25 years are reported by both, from 2000 to 2024.
- How do Norway and Saint Kitts and Nevis rank globally for immunization, hib3?
- Norway ranks 29th and Saint Kitts and Nevis ranks 29th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.